secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001564590-21-053950
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Q3 net loss $0.17/share; cash $216M; VK2809 VOYAGE trial ongoing
-----------------------------------------------------------------------

- Net loss of $13.2M ($0.17 per share) in Q3 2021 vs $9.3M ($0.13) in Q3 2020.
- Cash, cash equivalents and short-term investments of $216.1M as of Sept 30, 2021 ($248.4M at Dec 31, 2020).
- Phase 2b VOYAGE trial for VK2809 (NASH) enrolling; initial data expected in 2022.
- Phase 1b trial of VK0214 in X-ALD (AMN) underway; top-line results expected in 2022.
- Preclinical dual GLP-1/GIP agonists showed up to 27% body weight reduction; clinical development planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459021053950/0001564590-21-053950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459021053950/vktx-8k_20211103.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-053950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer